📣 VC round data is live. Check it out!
- Public Comps
- Biofrontera
Biofrontera Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biofrontera and similar public comparables like Passage Bio, AlzeCure Pharma, Neurothera Labs, Pasithea Therapeutics and more.
Biofrontera Overview
About Biofrontera
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.
Founded
1997
HQ

Employees
88
Website
Financials (FY)
EV
$13M
Valuation Multiples
Start free trialBiofrontera Financials
Biofrontera reported last fiscal year revenue of $15M and negative EBITDA of ($653K).
In the same fiscal year, Biofrontera generated $13M in gross profit, ($653K) in EBITDA losses, and had net loss of ($5M).
Revenue (LTM)
Biofrontera P&L
In the most recent fiscal year, Biofrontera reported revenue of $15M and EBITDA of ($653K).
Biofrontera is unprofitable as of last fiscal year, with gross margin of 83%, EBITDA margin of (4%), and net margin of (30%).
Financial data powered by Morningstar, Inc.
Biofrontera Stock Performance
Biofrontera has current market cap of $17M, and enterprise value of $13M.
Market Cap Evolution
Biofrontera's stock price is $2.75.
Biofrontera share price decreased by 8.4% in the last 30 days, and increased by 3.6% in the last year.
Biofrontera has an EPS (earnings per share) of $-0.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $17M | 0.4% | -8.4% | -13.4% | 3.6% | $-0.76 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiofrontera Valuation Multiples
Biofrontera trades at 0.8x EV/Revenue multiple, and (19.3x) EV/EBITDA.
EV / Revenue (LTM)
Biofrontera Financial Valuation Multiples
As of May 20, 2026, Biofrontera has market cap of $17M and EV of $13M.
Biofrontera has a P/E ratio of (3.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biofrontera Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Biofrontera Margins & Growth Rates
In the most recent fiscal year, Biofrontera reported gross margin of 83%, EBITDA margin of (4%), and net margin of (30%).
Biofrontera Margins
Biofrontera Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Biofrontera Operational KPIs
Biofrontera's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Biofrontera Competitors
Biofrontera competitors include Passage Bio, AlzeCure Pharma, Neurothera Labs, Pasithea Therapeutics, Diamyd Medical, Elicera Therapeutics, Scienture Holdings, Exact Therapeutics, Poxel and AcuCort.
Most Biofrontera public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| — | — | 0.3x | — | |||
| — | — | (2.8x) | (3.2x) | |||
| — | — | (86.8x) | — | |||
| — | — | 1.9x | 1.1x | |||
| 482.7x | — | (0.4x) | (0.4x) | |||
| — | — | (7.5x) | (6.0x) | |||
| 28.5x | 5.6x | (0.3x) | — | |||
| — | — | (1.5x) | — | |||
This data is available for Pro users. Sign up to see all Biofrontera competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biofrontera
| When was Biofrontera founded? | Biofrontera was founded in 1997. |
| Where is Biofrontera headquartered? | Biofrontera is headquartered in Germany. |
| How many employees does Biofrontera have? | As of today, Biofrontera has over 88 employees. |
| Is Biofrontera publicly listed? | Yes, Biofrontera is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Biofrontera? | Biofrontera trades under B8FK ticker. |
| When did Biofrontera go public? | Biofrontera went public in 2007. |
| Who are competitors of Biofrontera? | Biofrontera main competitors include Passage Bio, AlzeCure Pharma, Neurothera Labs, Pasithea Therapeutics, Diamyd Medical, Elicera Therapeutics, Scienture Holdings, Exact Therapeutics, Poxel, AcuCort. |
| What is the current market cap of Biofrontera? | Biofrontera's current market cap is $17M. |
| What is the current revenue of Biofrontera? | Biofrontera's last fiscal year revenue is $15M. |
| What is the current EV/Revenue multiple of Biofrontera? | Current revenue multiple of Biofrontera is 0.8x. |
| Is Biofrontera profitable? | No, Biofrontera is not profitable. |
| How many companies Biofrontera has acquired to date? | Biofrontera hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Biofrontera has invested to date? | Biofrontera hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Biofrontera
Lists including Biofrontera
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.